Inhibitors of glycogen synthase kinase 3
New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
Chiron Corporation
A C A C A A C A A A C A C A A C C C
A61P C07D A61P C07D A61P A61P C07D A61P A61P A61P C07D A61P C07D A61P A61P C07D C07D C07D
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Rustum S. Kirk W. David B. John M. Allan S. Paul A. Dane A. Lynn Stephen D. Sharadha Sean P. Xiaohui A. Savithri Keith B.
Boyce Johnson Ring Nuss Wagman Renhowe Goff Seely Harrison Subramanian Brown Zhou Ramurthy Pfister